216 related articles for article (PubMed ID: 21407219)
21. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.
Bhattacharya R; Fan F; Wang R; Ye X; Xia L; Boulbes D; Ellis LM
Br J Cancer; 2017 Sep; 117(6):848-855. PubMed ID: 28742793
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
[TBL] [Abstract][Full Text] [Related]
23. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
24. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
25. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
26. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Carneiro A; Falcão M; Pirraco A; Milheiro-Oliveira P; Falcão-Reis F; Soares R
Exp Eye Res; 2009 Mar; 88(3):522-7. PubMed ID: 19135441
[TBL] [Abstract][Full Text] [Related]
27. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
28. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
Molhoek KR; Griesemann H; Shu J; Gershenwald JE; Brautigan DL; Slingluff CL
Cancer Res; 2008 Jun; 68(11):4392-7. PubMed ID: 18519701
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Huynh H; Teo CC; Soo KC
Mol Cancer Ther; 2007 Nov; 6(11):2959-66. PubMed ID: 18025280
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Di Desidero T; Canu B; Schirripa M; Frumento P; Di Paolo A; Danesi R; Falcone A; Bocci G
Br J Cancer; 2011 Apr; 104(8):1262-9. PubMed ID: 21407216
[TBL] [Abstract][Full Text] [Related]
32. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
Moehler M; Frings C; Mueller A; Gockel I; Schimanski CC; Biesterfeld S; Galle PR; Holtmann MH
World J Gastroenterol; 2008 Jul; 14(26):4156-67. PubMed ID: 18636661
[TBL] [Abstract][Full Text] [Related]
33. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
[TBL] [Abstract][Full Text] [Related]
36. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
[TBL] [Abstract][Full Text] [Related]
37. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
[TBL] [Abstract][Full Text] [Related]
38. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
40. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
Pagani E; Ruffini F; Antonini Cappellini GC; Scoppola A; Fortes C; Marchetti P; Graziani G; D'Atri S; Lacal PM
Int J Oncol; 2016 Apr; 48(4):1581-9. PubMed ID: 26846845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]